Dr Timothy Jinks

Tim is Strategy Development Lead for drug resistant infections guiding the team developing the Wellcome trust’s strategic plan to address antimicrobial resistance.  In his preceding role in Wellcome’s Innovations Division he was responsible for a portfolio of over a dozen early stage product development projects covering therapeutics, diagnostic and devices spanning across therapeutic areas such as infectious diseases and oncology.   He also serves as Wellcome Trust board observer at Sentinel Oncology and is Non-Executive Director of Reviral Ltd.  Prior to joining the Trust in 2012 he has over a decade of industry experience, most recently as a consultant providing business development, licensing and commercial research services.  Previously he was a Business Development executive at BTG International working on licensing and IP development.  His industry experience started as senior scientist with Iclectus Ltd, a spin-out company from the MRC Laboratory of Molecular Biology, Cambridge that developed an antibody engineering platform.  He qualified as a professional chemist at the University of Georgia obtaining the ACS BS in Chemistry before gaining his MA and PhD in Molecular Biology at Princeton University with training at the Dana Farber Cancer Institute and Harvard Medical School. He conducted postdoctoral research at the National Institute for Medical Research at Mill Hill, London.

Session 4: International models and funding
Tuesday 4 April 
Chair: Professor Jian Li


Supported By